Menopause changes body composition, sleep, and how the body handles energy. Women in midlife are also a large share of the people asking about GLP-1 medications. Yet most obesity trials report one pooled average and move on, leaving a fair question open: does the average describe someone at your stage of life?
A new analysis tries to answer it for one drug. It is worth reading closely, partly for what it adds and partly because of what it can’t do.
What the analysis looked at
The work is a post hoc analysis of two phase 3 trials of orforglipron, an investigational-turned-marketed once-daily oral GLP-1 receptor agonist made by Eli Lilly. It was first presented at the American Diabetes Association meeting in June and again at the European Association for the Study of Diabetes meeting in late September.
Researchers took women from ATTAIN-1 (people with overweight or obesity, no diabetes) and ATTAIN-2 (people with overweight or obesity and type 2 diabetes), about 2,000 and 750 women respectively, and sorted them into premenopausal, perimenopausal, and postmenopausal groups. They then looked at the highest trial dose over 72 weeks.
Reported average weight change was similar across the three groups in ATTAIN-1, roughly 13 to 14 percent, and somewhat more varied in ATTAIN-2, where the perimenopausal group averaged lower than the other two. Waist circumference also fell in every group.
The takeaway as presented: the drug’s average effect did not appear to depend much on menopausal stage.
What a post hoc subgroup analysis does not establish
It was not designed to answer this question. The trials were built to compare orforglipron with placebo in the whole study population. Splitting the data afterward by menopausal status is a question asked after the results were in. The groups were not randomized to be premenopausal or postmenopausal, so there was no protection against the groups differing in age, baseline weight, or other characteristics.
Small groups make noisy estimates. Subgroups of a couple hundred women each can produce averages that wobble for reasons unrelated to biology. The lower perimenopausal figure in the diabetes trial may be real, or it may be sampling variation. Neither conclusion is supportable from this analysis alone.
“Similar on average” is not “the same for you.” An average that matches across groups says nothing about how widely individual results spread within each group. Trial averages do not predict a single person’s outcome, and the spread inside a subgroup can be wider than the gap between subgroups.
Averages hide what happened to people who stopped. Participants who discontinue a medication, often because of side effects, shape how results are reported and which analysis method is used. The summaries we reviewed do not break out side effects by menopausal status, so this analysis tells us little about tolerability at different stages.
The sponsor is involved. The trials were Lilly trials, and the senior author named in coverage is affiliated with Lilly. That does not make the data wrong. It does mean the choice of which subgroup cuts to run and publicize was not made by a disinterested party, and it is the kind of context a reader should have.
It says nothing about what menopause does to the people in it. The analysis looked at weight and waist measures. It did not examine hot flashes, sleep quality, bone density, or mood, which are often the things women in this life stage most want addressed.
Why it still matters
Women have historically been under-represented, or at least under-analyzed, in cardiometabolic research. Asking whether results hold up across life stages is the right instinct, and an analysis that finds no obvious fall-off is a reasonable reason to plan a study built to test the question properly. A prespecified, adequately powered analysis would tell us far more than this one can.
The part that applies to compounded medications
This analysis concerns a single manufactured, branded oral product studied under a regulatory trial program. Its results do not transfer to any compounded preparation. Compounded semaglutide and tirzepatide, the injectable medications NoBsRx provides provider-guided access to, are prepared by state-licensed 503A pharmacies for an individual patient. They are not FDA-approved and have not been through trials like ATTAIN, and orforglipron is a different molecule from either.
If any company uses a menopause-stage analysis of one drug as a selling point for a different product, treat it as a stretch past the evidence.
What to do with this
If you are in perimenopause or postmenopause and curious about GLP-1 medication, the honest summary is narrow. One drug’s trial data did not show an obvious difference by menopausal stage, in analyses not designed to prove that. Whether any medication is appropriate for you depends on your history, your other conditions, and the medications you already take, which is what a licensed provider’s review is for. You can see how that process works and read the common questions before deciding anything.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program and is not a claim that any medication will produce a particular result. Compounded medications are not FDA-approved. Treatment is never guaranteed. Eligibility and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment based on an article. If you have questions about menopause or your health, talk to a licensed clinician.